Biocon receives three observations from USFDA for its Insulin Glargine facility in Malaysia

Reader's Pick

India’s leading biopharma company Biocon on Saturday said that “It has received three observations for its insulin manufacturing facility in Malaysia from the United States health regulator.”

In a filing with the stock exchange, Biocon, said, “The pre-approval inspection for Insulin Glargine was conducted between February 10 and 21, by the US Food and Drug Administration (USFDA) at the Biocon Sdn Bhd’s manufacturing facility in Malaysia.”

The filing added, “After the inspection, the agency issued a Form 483 with three observations which we believe a procedural in nature.”

- Advertisement -

According to the USFDA, “Form 483, issued to the firm management after the inspection after investigators observed any conditions that in their judgment may constitute violations of the Food, Drug and Cosmetic Act and related Acts.”

“The FDA has set a target action date for its Insulin Glargine application in June 2020. The company will respond to the FDA with the appropriate Corrective and Preventive Action Plan (CAPA), and we are confident of addressing these observations expeditiously,” the company said.

The company further said, “We believe the outcome of this inspection does not in any way impact the commercialization of Insulin Glargine in the US. Biocon Biologics is committed to global standards of quality and compliance.”

- Advertisement -
Krishna Mali
Krishna Mali
Founder & Editor of TechGraph.

Latest News

Promoted Links

Related Stories

Bank of Japan keeps monetary policy steady, brings new forward guidance on rates

The Bank of Japan kept its monetary policy steady on Thursday but introduced new...

Employees union seeks FIR against Jet Airways boss Naresh Goyal, Vinay Dube and on SBI Chairman

The employee union of Jet Airways, which is facing its worst crisis, Friday sought...

Japan approves 26 trillion yen as economic stimulus package to combat overseas risks

Japan's cabinet approved an economic stimulus package worth 26 trillion yen ($239 billion) with...

Samsung Electronics asks its shareholders to use electronic voting for upcoming AGM

Technology giant Samsung Electronics has adopted electronic voting for the first time ever for...

Rahul Gandhi hits on RCEP says, ‘Make in India’ has become ‘Buy from China’

Asserting that "Make in India" has become "Buy from China," Congress leader Rahul Gandhi...

1Win App: Review India Apk for Android and iOS

The company 1Win has been successfully operating in the markets of many countries around...

Key Challenges that lie ahead for the Cyber security industry

The global pandemic triggered a need for digitization. While this has many advantages, it...

Jack Dorsey may not appear before Indian parliamentary Panel on 25 February

Twitter CEO Jack Dorsey will not appear before the Parliamentary panel on IT on...

An interview with Sajeev Nair, Founder of Vieroots Wellness Solutions

Speaking to the TechGraph, Sajeev Nair, Founder & Chairman, Vieroots Wellness Solutions said, "As...

How Ginesys retail ERP Software Can Solve 7 Common Manufacturing Problems

The retail industry is undergoing a massive transformation. Customers nowadays prefer shopping through multiple...

Top Ways To Keep Your Business Running Smooth

When it comes to the management of a company, it is almost unavoidable that...

In conversation with Paramdeep Singh Anand, CEO of FieldAssist

Today we speak to Paramdeep Singh Anand, CEO of FieldAssist to understand how FieldAssist...

Beginners Guide to Web3, Blockchain & Crypto Jobs

Web3, blockchain, and crypto have become comprehensive terms and have captured the world's attention...

Top 20 Google Slide Templates for Less than $20

Google Slides is a free presentation software accessible on any device through a browser....